PDE5 Inhibitors Archives

U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)

Approvals, Exercise, FDA/Regulatory, PDE5 Inhibitors, Pulmonary Arterial Hypertension, Therapeutics, WHO

First-Line Combination of Letairis and Tadalafil Reduced Risk of Disease Progression by Nearly 50 Percent Compared to Either Therapy Individually in Study of 605 PAH Patients with WHO Functional Class […]

October 2, 2015/by Business Wire